Zovaglutide: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข1 clinical studies cited
- โขOverall evidence level: low
- โข6 research gaps identified
Research Studies
Phase 2 Results of a Monthly Dose Study Evaluating Zovaglutide, a Novel, Extended Half-Life GLP-1 Receptor Agonist (EASD 2025)
QL Biopharm (Beijing QL Biopharmaceutical) (2025) โข Presented at EASD 2025
Randomized, double-blind, placebo-controlled phase 2 trial in 303 overweight or obese subjects evaluating zovaglutide at 80 mg and 160 mg given monthly (Q4W) or biweekly (Q2W) for 24 weeks. Met primary and all secondary endpoints.
Key Findings
- 160 mg Q4W: 13.8% body weight reduction at 24 weeks vs 2.4% placebo
- Weight loss range across dose groups: 10.6-14.4%
- GI discontinuation rate: only 1.3% (lower than marketed GLP-1 RAs)
- Met primary endpoint (% change in body weight) and all secondary endpoints
- Secondary endpoints included proportion achieving 5%, 10%, 15% weight loss
Limitations: 24-week duration (weight loss may not have plateaued); conference presentation without full peer-reviewed publication; predominantly Chinese population
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
0View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขPeer-reviewed publication of phase 2 data
- โขPhase 3 results with longer treatment duration (52+ weeks)
- โขEfficacy comparison in Western populations
- โขHead-to-head comparison with semaglutide or tirzepatide
- โขEffect on cardiometabolic parameters and cardiovascular outcomes
- โขLong-term weight maintenance and safety beyond 24 weeks
Research Overview#
Zovaglutide (ZT-002) has completed phase 1 and phase 2 clinical development, with data presented at major international conferences. The evidence base is currently limited to conference presentations, as peer-reviewed publications of the clinical data are not yet available. Despite this, the phase 2 results are notable for demonstrating competitive weight loss with once-monthly dosing and an unusually low GI-related discontinuation rate.
The evidence level is classified as low because the data come primarily from conference presentations without full peer-reviewed publication, and phase 3 results are not yet available.
Phase 1c Study (EASD 2024)#
Preliminary results from a phase 1c dose-ranging study were presented at EASD 2024, establishing the safety, pharmacokinetic, and preliminary efficacy profiles of zovaglutide. This study supported the dose selection for the phase 2 trial.
Phase 2 Trial (EASD 2025)#
The pivotal phase 2 trial was presented at the European Association for the Study of Diabetes (EASD) annual meeting in 2025.
Study Design#
- Design: Randomized, double-blind, placebo-controlled
- Population: 303 overweight or obese subjects
- Treatment groups: Placebo (n=51), zovaglutide 80 mg Q4W (n=75), 160 mg Q4W (n=76), 80 mg Q2W (n=50), 160 mg Q2W (n=51)
- Duration: 24 weeks (including dose escalation and maintenance)
- Primary endpoint: Percent change in body weight from baseline at 24 weeks
- Secondary endpoints: Proportion achieving 5%, 10%, 15% weight loss; absolute weight change; cardiometabolic risk factors; safety and tolerability
Key Efficacy Results#
| Group | Weight Loss at 24 Weeks | vs Placebo |
|---|---|---|
| Placebo | -2.4% | -- |
| 80 mg Q4W | ~10.6% | Significant |
| 160 mg Q4W | -13.8% | Significant |
| 80 mg Q2W | Evaluated | Significant |
| 160 mg Q2W | Up to ~14.4% | Significant |
- Both primary and all secondary endpoints were met
- Clear dose-response relationship
- The 160 mg Q4W (monthly) regimen achieved 13.8% weight loss -- a clinically meaningful result for a 24-week study with monthly dosing
Tolerability Profile#
A key finding was the low GI-related discontinuation rate:
- Overall GI adverse event incidence was similar to marketed GLP-1 RAs
- Only 1.3% of patients discontinued due to GI events
- This compares favorably to discontinuation rates of 4-8% typically seen with semaglutide and tirzepatide in phase 3 trials
- The slow, sustained drug release from the long half-life may contribute to better GI tolerability
Contextual Comparison#
Weight Loss at 24 Weeks#
For context, weight loss results from other GLP-1 RAs at similar timepoints:
| Agent | Duration | Weight Loss | Notes |
|---|---|---|---|
| Zovaglutide 160 mg Q4W | 24 weeks | -13.8% | Phase 2; monthly dosing |
| Semaglutide 2.4 mg (STEP 1) | 24 weeks | ~-12% (continuing to -15% at 68 wk) | Phase 3; weekly dosing |
| Tirzepatide 15 mg (SURMOUNT-1) | 24 weeks | ~-15% (continuing to -22% at 72 wk) | Phase 3; weekly dosing |
These comparisons must be interpreted cautiously due to differences in trial populations, designs, and endpoints.
Evidence Quality Assessment#
| Criterion | Assessment | Details |
|---|---|---|
| Study design | Phase 2 RCT | Double-blind, placebo-controlled |
| Sample size | 303 subjects | Adequate for phase 2 |
| Endpoints met | Primary + secondary | All endpoints significant |
| Peer review | Pending | Conference presentation only |
| Phase 3 | Initiated | Results pending |
| Population | Primarily Chinese | Western population data needed |
Key Research Gaps#
-
Peer-reviewed publication: The phase 2 data are currently available only as a conference presentation. Full publication with detailed methods and results is needed.
-
Phase 3 results: Longer-duration trials with larger, more diverse populations are needed to confirm efficacy and establish the weight loss plateau.
-
Head-to-head comparisons: Direct comparison with semaglutide or tirzepatide would clarify zovaglutide's competitive position beyond cross-trial comparisons.
-
Cardiovascular outcomes: Whether the weight loss and metabolic benefits translate to reduced cardiovascular events is unknown.
-
Western population data: Efficacy and tolerability may differ in non-Chinese populations, which needs to be established for global regulatory approval.
Related Reading#
Frequently Asked Questions About Zovaglutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.